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Potassium channels are the most heterogeneous and widely distributed group of ion channels and play important functions in
all cells, in both normal and pathological mechanisms, including learning and memory processes. Being fundamental for many
diverse physiological processes, K+-channels are recognized as potential therapeutic targets in the treatment of several Central
Nervous System (CNS) diseases, such as multiple sclerosis, Parkinson’s and Alzheimer’s diseases, schizophrenia, HIV-1-associated
dementia, and epilepsy. Blockers of these channels are therefore potential candidates for the symptomatic treatment of these
neuropathies, through their neurological eﬀects. Venomous animals have evolved a wide set of toxins for prey capture and defense.
These compounds, mainly peptides, act on various pharmacological targets, making them an innumerable source of ligands for
answering experimental paradigms, as well as for therapeutic application. This paper provides an overview of CNS K+-channels
involved in memory acquisition and storage and aims at evaluating the use of highly selective K+-channel blockers derived from
arthropod venoms as potential therapeutic agents for CNS diseases involving learning and memory mechanisms.
1.Introduction
Many eﬀortshavebeenmadetounderstandthephysiological
mechanisms responsible for learning and memory. Due to
their complexity, diﬀerent approaches have been used to
unlock them and various actors of these phenomena have
beenoftenrevealed[1,2].Inthelasttwodecades,anewagent
hasgainedtheattentionofthescientiﬁccommunitystudying
the processes of learning and memory: the potassium chan-
nels [3].
Potassium channels (KCNs) exhibit a great diversity (for
review see [4, 5]). In mammals, nine and ten genes that
encode channels for Na+ and Ca2+ have been described,
respectively. Nonetheless, for KCN they are 78 genes, at least
[5]. In addition to this large number of genes, alternative
splicing, RNA editing, posttranslational modiﬁcations, and
channel formation of heteromeric assembly by the associ-
ation of diﬀerent principal subunits also contribute to the
diversity of KCN [4]. These channels can be grouped into
four families: voltage-gated channels (Kv), calcium-activated
channels (KCa), inward-rectiﬁers channels (Kir) and two
tandem-pore channels (K2P). Furthermore, these families
have many subfamilies each containing several members:
Kv have 12 subfamilies (Kv1-Kv12), KCa, 5 subfamilies
(KCa1-KCa5), the Kir, 7 subfamilies (Kir1-Kir7), and K2P,
15 subfamilies (K2P1-K2P7, K2P9,K2P10, K2P12, K2P13 and
K2P15-K2P18) [6–9].
The four families of KCNs are structurally related. Kv,
Kir,a n dK Ca are transmembrane proteins formed by four α-
subunits, whereas in K2P there are only two. α-Subunits of
all Kv,K Ca2, and KCa3 have six transmembrane segments
(6TM), while in KCa1, KCa4, and KCa5a r e7 T M .A l lK ir
have α-subunits with 2TM and those of K2P contain 4TM.
When α-subunits join to form a channel, they may be iden-
tical and thus generating homodimeric or homotetrameric
(homomultimeric) channels or may be diﬀerent resulting2 Journal of Toxicology
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Figure 1: Views of the Kv1.2-β2 subunit complex. (a) Side view of the Kv1.2-β2 structure with the extracellular solution above and the
intracellular solution below. Four subunits of the channel are colored in yellow (T1 domain and voltage sensor) and green (pore). β subunit
tetramer is colored in red. TM indicates the integral membrane component of the complex. (b) Stereoview of a single subunit of the channel
and β subunit viewed from the side. Labels correspond to six transmembrane helices (S1 to S6). (c) View of the Kv1.2-β2 structure from the
extracellular side of the membrane. S1–S4 helices from each subunit form four surrounding voltage-sensing domains, S5-S6 regions (green)
from the four subunits shape a single pore domain. Purple spheres are potassium ions. Images were generated using Protein Workshop
Viewer 3.9 [15] and Protein Data Bank accession ID 2A79 [14].
in heterodimeric or heterotetrameric (heteromultimeric)
channels. Heteromultimeric channels are formed by the
association of diﬀerent α-subunits of the same subfamily. α-
Subunits assembly of K2P forms two pores and the in other
KCNs there is one pore (for reviews, see [4, 5, 10–13]).
The X-ray structure of mammalian Kv1.2 channel with the
β2 subunit (Figure 1) was reported by Long et al. [14]. In
accordance with what is mentioned above, Kv channels are
formed by four α-subunits that generate one pore (Figures
1(a) and 1(c)). Each Kv1.2 channel subunit contains six
transmembrane segments, termed S1 to S6 (Figure 1(b)).
The S5-S6 regions (Figures 1(a)–1(c), green) from the four
subunits shape a single pore domain. The S1-S4 helices
from each subunit form four surrounding voltage-sensing
domains (Figures 1(b) and 1(c)).
KCNs have a signiﬁcant inﬂuence on the neuron’s
activity,functioningofneuronalcircuits,andbrainplasticity.
These channels regulate action potential ﬁring patterns
and control neurotransmitter release by constraining local
membrane excitability and limiting Ca2+ inﬂux (for review,
see [16]). Furthermore, KCNs participate in the induc-
tion of synaptic plasticity by shape excitatory postsynaptic
potentials(EPSPs)andenhancesynapticintegrationthrough
their N-methyl-D-aspartate receptor (NMDAR), the cellular
analogue for learning and memory (for review, see [3]).
Therefore, KCNs may have an important role in cognition.
This possible involvement of KCN in cognitive processes
is reinforced by its strong presence in Central Nervous
System(CNS).Thesechannelshaveawidedistributioninthe
brain of mammals. Several members of the Kv families [17–
20], KCa [21–25], Kir [26–29], and K2P [30, 31], are found in
the telencephalon, diencephalon, brainstem, and cerebellum
of mammals.
The use of KCN blockers has aided to elucidate the
function of these channels in the CNS. The tetraethylam-
monium (TEA) and 4-aminopyridine (4-AP) are traditional
(classical) pharmacological blockers for KCN [32]. However,
they are not speciﬁc, neither act on all types of KCN. TEA
blocksdiﬀerentsubtypesofKv channels(exceptKv4.2,Kv4.3,
Kv5.1, Kv7.1 and all of the subfamilies Kv6, Kv8-Kv12), KCa
(except subfamily KCa2a n dK Ca3), and subtypes Kir3.4 and
Kir7.1, but has no eﬀect on K2P channels (for review see
[6–9]). The 4-AP also operates on diﬀerent subtypes of Kv
channels (except Kv3.4, Kv5.1, and all Kv6-Kv12), Kir3.4, andJournal of Toxicology 3
Kir7.1, but not on KCa channels, neither on the K2P [6–9].
Therefore, the potential of these blockers to investigate the
role of KCN on cognitive processes is limited.
Their diversity, distribution, and function suggest that
the potassium channels could be involved in diﬀerent cogni-
tive processes, leading to a complex scenario that embarrass
the understanding of the role of each K+-channel subtype in
these events. This challenge is even more complicated by the
lack of drugs that act speciﬁcally on each type of KCN. One
way to solve this problem has been the use of toxins isolated
from invertebrates’ venoms as K+-channels blockers.
Many animal toxins, such as those isolated from spider,
scorpion, and bee venoms, are speciﬁc blockers of potassium
channels. While TEA operates in millimolar concentrations,
scorpion toxins bind to and block Kv channels with pico- or
nanomolar aﬃnities [33]. Apamin, a toxin isolated from the
bee venom, blocks KCa2.2 and KCa2.3 channels with aﬃnity
of the order of picomolar [34]. Therefore, animal venom
toxins may be more useful as pharmacological tools than the
classicalblockers(TEAand4-AP)astheyactonK+-channels
with high potency and selectivity [35].
Theaimofthispaperistoreviewtheknowledgeaccumu-
lated on the importance of KCN to the processes of learning
and memory. In addition, we present the contribution and
potential use of toxins isolated from spiders, scorpions, and
bees as pharmacological tools in this investigation. Finally,
the participation of KCN in clinical conditions holding
cognitive deﬁcits and the possible use of toxins from animals
as therapeutic agents are also considered.
2. PotassiumChannelsinLearningandMemory
The hippocampus has a great importance in learning and
memory processes. This limbic structure holds a key in the
consolidation of explicit memory. It receives information of
events and transfers them to the neocortex where they are
stored for a period (even weeks) and then gradually returned
to speciﬁc regions of the cerebral cortex contributing to the
formation of long-term memory [36].
The hippocampus expresses many types of KCN. As
shown in Table 1,3 9d i ﬀerent types of KCN belonging to the
four families (Kv,K Ca,K 2P,a n dK ir) have been identiﬁed in
this neural structure. Of these, the more expressed channels
in the hippocampus appear to be the Kv7.2, Kv7.3, KCa1.1,
Kir3.2, and Kir3.3, followed by Kv1.1, Kv1.6, Kv3.1, Kv4.2,
Kv10.1, KCa2.1, KCa2.2, and Kir3.1 (Table 1). What would be
the role of this KCN diversity in the hippocampus?
Manyexperimentalstudies(Table 2)showthatKCNmay
have a signiﬁcant contribution in learning and memory
processes. In these studies, the activity or expression of K+
channelsinthebrainofratsandmicewasalteredbydiﬀerent
strategies. The impact of this manipulation on the learning
and memory was accessed by behavioral tests.
Ghelardini et al. [50] worked with mice subjected to
passive avoidance test (Table 2). They found that intracere-
broventricular (i.c.v.) administration of minoxidil, pinacidil,
and cromakalim (KCN openers) produced amnesia. How-
ever, TEA, gliquidone and glibenclamide (KCN blockers)
prevented this eﬀect. These researchers also used toxins
(apamin and charybdotoxin) whose results will be addressed
later in the present paper.
Vick et al. [53] studied mice submitted to object
recognition task, contextual fear-conditioning paradigm,
and tone fear-conditioning paradigm (Table 2). Systemic 1-
ethyl-2-benzimidazolinone (EBIO) and cyclohexyl-[2-(3,5-
dimethylpyrazol-1-yl)-6-methyl-pyrimidin-4-yl]-amine
(CyPPA), KCa2 channel activators, impaired the encoding,
but not retrieval, of object memory in a spontaneous object
recognition task. In addition, EBIO did not aﬀect contextual
or cued fear memory. They also tested apamin and this
treatment will be discussed in Section 4.1.
Matthews and Disterhoft [54] observed rats submitted
to trace eyeblink conditioning (Table 2). Intrahippocampal
(CA1) injection of paxilline, a KCa1.1 channel blocker,
resulted in slowed learning of the task.
Hammond et al. [55] produced transgenic mice that
overexpress KCa2.2 subunits by 10-fold and tested them by
Morris water maze, contextual fear-conditioning paradigm,
and tone fear-conditioning paradigm on mice (Table 2).
They found that this condition impaired learning in all
tasks. The same results for these animals in contextual fear-
conditioning paradigm were obtained for Stackman et al.
[56].
Jacobsen et al. [57] tested doxycycline-induced condi-
tional KCa2.3-deﬁcient mice in ﬁve distinct learning and
memory paradigms: passive-avoidance test, Morris water
maze test, object recognition task, Y-maze test, and ﬁve-trial
inhibitory avoidance test. Impairment was only observed in
the last two tasks (with no eﬀect on the others).
Deng et al. [58]w o r k e dw i t hr a t ss u b j e c t e dt oM o r r i s
water maze test (Table 2). They infused small interfering
RNA (siRNA) in the entorhinal cortex (EC) to knock down
K2p10.1 channels. Baclofen, a speciﬁc γ-aminobutyric acid
(GABAB) receptor agonist, was also applied into EC. The
treatment of rats with siRNA abolished baclofen-induced
inhibition of spatial learning. When administered alone,
siRNA tended to improve the learning ability of rats.
Wickaman et al. [46] employed mice lacking a functional
Kir3.4 gene and submitted them to passive-avoidance test
and Morris water maze test (Table 2). These mice performed
similarly to wild-type controls in the ﬁrst task, however,
exhibited impaired performance in latter.
Betourne et al. [48] worked with wild-type and Kir6.2
knockout mice submitted to Morris water maze test, contex-
tual fear-conditioning paradigm, and tone fear-conditioning
paradigm (Table 2). In wild-type mice, intra-hippocampal
(CA3) injection of diazoxide (Kir6.2 opener) impaired
contextual memory. This eﬀect was reversed by co-injecting
tolbutamide (Kir6.2 blocker). The Kir6.2 knockout mice
presented impairment of contextual and tone memories and
slightly impaired performance in Morris water maze (special
memory).
It has been described that Kv1.1 channels contribute to
the processes of learning and memory. Meiri et al. [51]w e r e
able to inhibit the expression of Kv1.1 in the hippocampus,4 Journal of Toxicology
Table 1: Distribution of diﬀerent types of K+ channels in hippocampus.
Channels
Hippocampus
Employed technique Ref.
CA1 CA3 DG
Kv1.1 ++ +++ +++ ISH, IMH, IMC, and CIMP in hippocampus or
brain of rat, mouse, or gerbil. [37–39]
Kv1.2 + + ++
Kv1.3 −−− IMH in gerbil hippocampus. [39]
Kv1 . 4+ ++ ++ + ISH, IMH, and IMC in hippocampus or brain of rat,
mouse or gerbil. [20, 38, 39]
Kv1.5 + + − I M Ho rs i n g l e - c e l lR T - P C Ri ng e r b i lo rr a t
hippocampus. [39, 40]
Kv1.6 ++ +++ +++ IMH in gerbil hippocampus. [39]
Kv2.1 ++ ++ Single-cell RT-PCR in rat hippocampus. [17]
Kv3.1 ++ +++ +++
Northern blot analysis and ISH in rat brain. Kv3.2 +++ ++ − [17]
Kv3.3 + + ++
Kv3.4 −− ++
Kv4.1 + + ++ ISH in rat brain. [18]
Kv4.2 +++ ++ +++ ISH or IMH in rat or mouse brain. [18, 41, 42]
Kv4.3 + ++ +++ ISH in rat brain.
[18, 42] Kv7.2 +++ +++ +++ ISH and IMH in rat brain
Kv7.3 +++ +++ +++
Kv10.1 ++ +++ ++ ISH, real time PCR, or IMH in rat brain. [19, 43]
Kv10.2 −−−
ISH and IMH in rat brain.
Kv11.1 ++ −−
Kv11.2 −−− [19]
Kv11.3 +++ −−
Kv12.1 + − +
Kv12.2 ++ − ++
KCa1.1 +++ +++ +++ ISH, WB analysis, IMH, IMF, IMC, or RLB in mouse
or rat brain. [21, 22, 44]
KCa2.1 ++ +++ ++ ISH, IB analysis, IMH, or RLB in rat brain. [23, 24]
KCa2.2 +++ +++ + ISH, IB analysis, IMH, or RLB in rat brain. [23–25]
KCa2.3 + ++ +
K2P1.1 − ++ ++ ISH in rat and mouse brain.
K2P2.1 ++ + +++ ISH, WB analysis, IMH, IMF, or IMC in rat or
mouse brain. [31]
K2P3 . 1 + ++ ++ +
ISH in rat and mouse brain. K2P4.1 ++ +++ + [31]
K2P9.1 ++ ++ +++
K2P10.1 − ++ +
Kir2.1 + + +++ ISH or IMH in mouse or rat brain. [26–28]
Kir2.2 ++ + ++ ISH in mouse or rat brain. [26, 27]
Kir2.3 ++ + +++
Kir3.1 +++ ++ +++ ISH or IMH in rat brain. [27, 28]
Kir3.2 +++ +++ +++ ISH or IMH in rat brain. [27, 45]
Kir3.3 +++ +++ +++ ISH in rat brain [27]
Kir3.4 + ++ + WB analysis, IMH or ISH in rat or mouse brain. [27, 45–47]
Kir6.2 ++ ++ ++ ISH, IMH, or IMF in rat or mouse brain. [29, 48, 49]
The symbols indicate signal intensity as follows: − (not detected); + (weak); ++ (moderate); +++ (high); CA1, CA3, and DG (Dentate gyrus) are regions
of hippocampal formation; Ref.: reference; RT-PCR means reverse transcription polymerase chain reaction; ISH is used for in situ hybridization; IMH for
immunohistochemistry; IMC for immunocytochemistry; CIMP for coimmunoprecipitation; IMF for immunoﬂuorescence; WB for western blot; IB for
immune blot; RLB for radioligand binding.Journal of Toxicology 5
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blocking the translation of the mRNA of these channels.
They found that this procedure worsened the passive avoid-
ance in mice and spatial memory in rats (Table 2). Kourrich
et al. [59], working with odor-discrimination tasks in rats,
showed that levels of mRNA expression of Kv1.1 channels in
the hippocampus were positively correlated with associative
learning.
On the other hand, Kv2.1 channels appear to interfere
negatively with learning and memory. Zhong et al. [40]
suggested that memory deﬁcits induced by scopolamine in
rats may result from exacerbation of potassium currents
in hippocampal pyramidal neurons as a consequence of
increased mRNA expression of Kv2.1 channels.
It has been shown that Kv12.2 (BEC1) channels have
preferential distribution in the forebrain, including the
hippocampal and cortical regions [19, 60, 61]. The use of
Kv12.2 knockout and overexpression (OVER) mice made
possible to verify that this KCN is negatively involved
in cognitive function, since the Kv12.2 knockout mice
performed behavioral tasks related to working memory,
reference memory, and attention better than their wild-
type animals. In the OVER mice, on the other hand, the
performance of those tasks was impaired [52]( Table 2).
Taken together, these studies strongly suggest that the
brain KCNs and their modulation play an important role
in the regulation of memory processes. Some hippocampal
Kv (Kv1, Kv2a n dK v12), KCa (KCa1eK Ca2), and Kir (Kir3e
Kir6) channels seem to be particularly relevant. On this basis,
the KCN blockers could be useful in investigation and the
treatment of cognitive deﬁcits.
3. Arthropod K+ ChannelsToxins
Arthropod venoms constitute a rich source of peptidyl KCN
inhibitors (KTxs). There are two classes of inhibitory pep-
tides based on their mechanism of action: (1) KCN blockers
which bind to the outer vestibule and then blocking the ion
conductancebytheporeocclusion;(2)KCNgatingmodiﬁers
which shift the channel opening to more positive potentials.
Scorpion KCN blockers (scorpions KTxs), exempliﬁed by
charybdotoxin (ChTX) [62], and the peptide tertiapin,
isolated from bee venom [63], act as pore blockers, while
spider KTxs, such as SGTx1 [64], act as a gating modiﬁer. In
turn, apamin, another toxin from bee venom, possibly acts
as a pore blocker, although residues of the extracellular S3/S4
loopoftheKCa2(SK)channelsalsoaﬀecttheapaminbinding
[65]. According to Lamy et al. [66], based on diﬀerences in
binding aﬃnity and potency of the blockage, apamin does
not behave as a classical pore blocker, and probably the
blocking eﬀect occurs by an allosteric mechanism.
These KTxs show diﬀerent arrangement of their three-
dimensional (3D) structures. The folding types earlier found
are αα, αββ,a n dβαββ [67–69]. Despite the conformation
diﬀerences, most of these peptides have common residues
which promote the binding with the potassium-channel
vestibule, such as a lysine residue distant from an aromatic
residue for 6.6 ±1.0 ˚ A[ 70].
Arthropod toxins have been used as pharmacological
tools to better understand the role of ion channels, as
most of them act in a high speciﬁc and potent way. Some
of these toxins constitute unique blockers of certain ion
channels, such as ergtoxin-1 (Centruroides noxius)[ 71],
and BeKm-1 (Mesobuthus eupeus)[ 72]f o rK v11.1 (HERG),
psalmotoxin (Psalmopoeus cambridgei) for ASIC1a channel
[73], tertiapin-Q (Apis mellifera)f o rK ir3.1 (GIRK) [63], and
Lq2 (Leiurus quinquestriatus hebraeus)f o rK ir1.1 (ROMK1)
[74].
The scorpion KTxs are formed by 20–95 amino acid
residues stabilized by two, three, or four disulﬁde bonds,
making this structure relatively stable. The scorpion KTxs
were originally classiﬁed into three families named α, β,
and γ [75], all of them have the highly conserved sec-
ondary structural arrangement α/β stabilized by cysteines
(CSα/β). More recently, scorpion KTxs presenting a diﬀerent
structural arrangement, with only two α-helices stabilized
by two disulﬁde bonds, CSα/α, were described, and these
peptides were named κ-KTxs [76–78]. Among the almost
190 scorpion KTxs described until now, the α-KTx family,
the largest one, contains more than 130 peptides thus far,
classiﬁed in 20 subfamilies, based on their amino acid
homology [75, 79].
Toxins from spider venom can play an important and
complementary role in investigation of KCN cognitive
function. Unlike most animal toxins obtained from snakes,
bees, scorpions and sea anemones venom, which block
mainly Kv1a n dK v3 channels, peptide toxins from spiders
target Kv2a n dK v4 channels, which are expressed in the
CNS and cardiovascular system of mammals (for review
see [80]). Moreover, the venom spiders belonging to the
Theraphosidaefamilyrepresentaplentifulsourceofpeptides
that modify the gating of Kv channels [81]. Hanatoxin
and seemingly others tarantula toxins shift channel opening
to more depolarized voltages [81, 82] by stabilizing the
resting conformation of the voltage sensor [83]. It has been
suggested that these peptides interact with the voltage-sensor
paddle within the lipid membrane [84–86].
Thebeevenomiscomposedofseveralclassesofpeptides,
aswellasenzymesandbiogenicamines.Amongthepeptides,
it can be emphasized the presence of the melittin [87],
apamin [88], tertiapin [89], and mast cell degranulating
peptide [90]. Certainly, in relation to neurotoxins, the
apamin has greatly excelled, since this peptide has been
considered a good pharmacological tool and it has provided
important information in respect of the functioning of K+
-channels [91].
4. Arthropod KTxs inLearningandMemory
As already mentioned above, KCN classical blockers are not
speciﬁc and cannot act at all KCNs. So these blockers have
a major limitation as tools for studying the role of KCN in
the CNS. An alternative to this obstacle is the use of KTxs
from arthropods venom. In this section we report studies
using these toxins to access the mechanisms of learning and
memory in animals submitted to behavioral tests. Table 3
presents a summary of these works. Analyzing this table, we
can see that the apamin is the most used KTx in tasks of
learning and memory, as detailed below.8 Journal of Toxicology
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4.1. Apamin. Apamin is a small peptide that corresponds
to less than 2% of bee venom dry weight. Its amino
acid sequence was described independently by two groups,
revealing completely its primary structure [104]. Like many
other peptide neurotoxins, apamin has high cysteine content
and a high basicity, but apamin is diﬀerent from most
peptide toxins in its unusual ability to cross the blood brain
barrier and act on the Central Nervous System [105]. This
peptideisapolypeptideof18aminoacidshavingamolecular
weight of 2039Da, with two disulﬁde bridges connecting
position 1 with 11, and position 3 with 15 [106]. According
to Vincent et al. [107], the most important part of the
apamin sequence for neurotoxic activity appears to be the C-
terminal region containing the two arginine residues, given
that chemical modiﬁcation of Argl3 and Arg14 eliminates
toxicity (DL50 in mice). Assays with autoradiography of
binding sites for apamin revealed that it binds preferentially
to the hippocampus, to the habenular nucleus, and to the
nucleus medialis septi [108].
Apamin is an antagonist of all three subtypes of small
conductance Ca2+-activated K+-channel, KCa2 channels.
However, this KTx showed subtype-speciﬁc aﬃnity demon-
strated by values of half maximal inhibition (IC50) and,
dissociation constant (Kd) for KCa2.1 (SK1), KCa2.2 (SK2),
and KCa2.3 (SK3) (IC50 = 704pM, 27pM, 4nM and Kd
390pM, 4pM, 11pM, resp.) [34]. As a consequence of
pharmacological blockage, apamin has been considered as
a useful tool to investigate the physiological mechanisms
involved in higher brain functions, especially cognitive
processes or in the control of mood [98, 109].
This bee KTx facilitates spatial and nonspatial learning
and improves memory performance in laboratory rodents,
accelerating the acquisition of bar-pressing response in
appetitively motivated mice [94]. In that report, when
apamin was injected (dose 0.2mg/kg, i.p.) 30min before the
acquisitionsession,itacceleratedlever-presslearningandthe
performance in a retention session 24h later in BALB/mice.
Results showed that immediate administration improved
the retention of the lever-press task one day later [94].
Additionally,administrationoftheapaminintheacquisition
of the lever-press task produced a stronger increase in early
geneexpression,c-fosandc-jus,intheCA1,CA3,anddentate
gyrus as compared to trained saline-injected mice [110]. The
similar pattern of immediate genes has been observed in the
initialactivationofneuronsduringthememoryprocess[99].
Moreover, Deschaux et al. [95] showed that injection
of apamin (0.4mg/kg i.p.) before the training improved
learning in an object recognition task in rats. Emphasizing,
they found that rats injected with apamin before the ﬁrst
exploration session spent more time in exploring the new
object than the familiar object at the second trial, when
it took place 24h after the ﬁrst trial. Injection of apamin
just after the ﬁrst trial or before the second trial did not
modify the diﬀerence in exploration time between the new
and the familiar object. These results suggest that apamin
could improve learning, but not consolidation or restitution
of the information, in an object recognition task [95].
Also in 1997, Deschaux and Bizot [96] reported that,
in the habituation task, apamin (0.4mg/kg, i.p) decreased
activity (distance travelled and rearing) on the restitution
sessionsonlywhenitwasinjectedbeforeacquisitionsessions,
but not when injection took place just after the acquisition
session or before the restitution session. In addition, the
authorsshowedthatinthepassiveavoidancetest,apamindid
not alter performance whenever the time of administration.
According to Deschaux and Bizot [96], blockage of the
apamin sensitive KCa channels improved the acquisition in
nonstressful task, but not in a stressful situation in rats.
In the water maze spatial navigation, apamin (0.2 and
0.06mg/kg, i.p) administered 30min before daily training
improved the acquisition and reversal learning of septal-
lesioned mice, but it did not improve learning and memory
in a spontaneous alternation task in a Y-maze and in a
passive avoidance task, and did not aﬀect learning and
memory in any of three tasks when intact mice were used as
subjects [97]. Interestingly, apamin dose dependently (0.2–
0.06mg/Kg, i.p) reversed the lesion-induced defect in the
radial arm maze and in the water maze [99]. These results
corroborated that blockage of KCa channels can alleviate
the spatial reference memory and working memory defect
induced by a damaged septohippocampal axis [99].
Van Der Staay et al. [98]m a k eac o m p r e h e n s i v es t u d y
using series of cognition tests with mice and rats from
diﬀerent strains. They used the standard version and a
modiﬁed version of the Morris water escape task, the passive
and active avoidance tasks, and the operant tasks in the
Skinner box as cognitive tests, and the rat forced swimming
test and the open-ﬁeld test after cocaine administration as
noncognitive tests. Results showed that apamin appeared to
improve the cognitive performance of mice in two versions
of the Morris water escape task and the passive avoidance
task. However, inconsistence evidence was identiﬁed in rats.
Moreover, apamin aﬀected the general behavior of rats in the
visual discrimination task, in the forced swimming test, and
in the open ﬁeld after cocaine administration [98].
In 2001, it was tested the eﬀect of an i.c.v apamin (0.3ng)
injection on an olfactory associative task. Apamin did not
modify the learning of the procedure side of the task or
the learning of the odor-reward association. To speciﬁcally
test reference memory, the rats were trained on a new odor-
association problem using the same procedure (acquisition
session), and they were tested for memory retention 24h
later. Apamin injected before or after the acquisition session
improved retention of the valence of a new odor pair. Thus,
the results indicate that the blockage of apamin-sensitive
KCa2 channels facilitates reference memory [100].
I no r d e rt oi n v e s t i g a t et h ee ﬀect of potassium channel
subtypes on rats learning and memory, Mpari et al. [101]
compare the eﬀects of two blockers, apamin (0.3ng) and
lei-Dab7 (3ng), a modiﬁed scorpion KTx that selectively
blocks KCa2.2 [111]. The results indicated that the block-
age of KCa2.2 and KCa2.3 channels by apamin facilitates
consolidation on new odor associations, using olfactory
associative task in rats. However, lei-Dab7 remains without
eﬀect suggesting an involvement of KCa2.3 channels for the
integration of synaptic signaling and plasticity modulation
involved in learning and memory processes [101].10 Journal of Toxicology
In the same way, in a spatial radial-arm maze task with
rats, it was shown that lei-Dab7 did not modify attention
or memory. However, apamin (speciﬁc to KCa2.2 and KCa2.3
channels) improved reference memory and accelerated strat-
egy changes from egocentric to allocentric. These results
reinforcethatKCa2.3blockageimprovesmemoryinrats[25].
Apamin is also able to facilitate the encoding of contex-
tual fear memory during the limited 1 conditioned stimulus-
unconditioned stimulus pairing protocol. It was shown that
mice treated with apamin exhibited signiﬁcantly greater
freezing during the context test than did the saline-treated
control [53].
More recently, the role of KCa in memory formation was
explored in chicks trained on a single-trial discrimination
avoidance task. Blockage of KCa2 channels using apamin
(1nM, 0.02ng/hem, i.c.) impaired long-termmemory reten-
tion when administered between 10min before, and 30min
after training [103].
Blockage of KCa2 channels in the prefrontal cortex (PFC)
by apamin also improves working memory performance
[102]( Table 3). In prefrontal, visual, and somatosensory
cortical pyramidal neurons, KCa2 channels mediate a hyper-
polarizationfollowingcalcium-inducedcalciumrelease,trig-
gered by activation of muscarinic [112, 113]o rg l u t a m a t e
receptors [114]. The PFC is central for working memory,
the aptitude to internally symbolize information without
an external input, being fundamental for establishing con-
ceptual thinking, and for language, for example. As KCa2
channels play an important role in diminishing the excitabil-
ity during synaptic transmission in the medial prefrontal
cortex (mPFC), their blockage could potentiate synaptic
transmission optimizing activity within the mPFC network
[115, 116].
All these studies suggest that KCa2 channels are involved
in memory processes but only when the task does not
implicate a spatial strategy or a stressful situation. Since
apamin is eﬀective in some of these examples, but fails to
have an eﬀect in others, it appears that apamin-sensitive
channels aﬀect only certain circuitries involved in memory
processing. Van Der Staay et al. [98] discuss the use of
apamin as a tool to study the role of potassium channels in
learning and memory. They do not consider apamin a good
tool, despite its high selectivity, because the peptide has a
very narrow therapeutic window, since there is an apparent
overlap between the doses that enhance cognition with those
causingsideeﬀects.Evenso,studiesusingapaminareofgreat
importancefortheunderstandingofthesechannelsandtheir
inﬂuence on processes of learning and memory.
4.2. Charybdotoxin. Charybdotoxin (α-KTx 1.1, ChTX-Lq1,
or ChTx-a), isolated from Leiurus quinquestriatus hebraeus
(Yellow scorpion) [117], is a potent selective inhibitor of
high (large or big) conductance Ca2+-activated potassium
channels (KCa1.1, BK, or maxi-K), as well as a Kv1.3
channel [62]. In an autoradiographic study of rat brain
it was demonstrated high levels of [125I]-charbydotoxin in
white matter regions such as the lateral olfactory tract and
fasciculus retroﬂexus, as well as in gray matter-containing
regions such as the zona incerta, medial geniculate, and
superior colliculus [118].
Using a [14C]-2-deoxyglucose autoradiographic tech-
nique, it was shown that i.c.v. administration of charyb-
dotoxin produced eﬀect on glucose utilization in 21 brain
regions predominantly limited to the hippocampus, limbic
and motor structures, indicating that glucose utilization was
altered within three pathways implicated within learning and
memory processes, the septohippocampal pathway, Schaﬀer
collaterals within the hippocampus, and the Papez circuit.
These results suggested the possibility that handling of
particular subtypes of Kv1 channels by speciﬁc scorpion
toxins in the hippocampus and related structures could alter
cognitive processes without provoking large-scale changes in
neural activity throughout the brain [119].
Ghelardini et al. [50] showed that the i.c.v. adminis-
tration of charybdotoxin, 20min before the training ses-
sion in the mouse passive avoidance test, prevented the
amnesia induced by potassium-channel openers (minoxidil
and pinacidil). The amnesia in mice was produced by
opening the KATP potassium channels, and it was reversed by
blocking KATP potassium channels. Since the prevention of
the amnesia induced by KATP potassium channel openers in
themousepassive-avoidancetestisalsoobtainedbyblocking
voltage-gated and calcium-activated channels, it is plausible
to consider that more than one type of KCN appears to
be involved in cognitive processes. It is worth mentioning
that KCN blockers used by Ghelardini et al. [50] did not
improve cognitive abilities when given alone, contrasting
with the ﬁndings showing that apamin enhances memory
in an object recognition task [95]. In fact, apamin, as it
blocks KCa channels, aﬀects learning rather than memory, an
eﬀectthatisnoticeableonlyinanobjectrecognitiontaskand
that was observed after an interval of 24h, when the control
animals were not able to remember the exploration of the
objects presented in the ﬁrst session anymore [50].
4.3. Kaliotoxin. Kaliotoxin is a speciﬁc inhibitor of Kv1.1 and
Kv1.3 isolated from the scorpion Androctonus mauretanicus
mauretanicus [120]. The involvement of Kv1.1 and Kv1.3
in learning and memory processes was studied by using
kaliotoxin in rats submitted to olfactory associative learning.
Kaliotoxin (10ng) improved learning but not information
consolidation in the odor-reward training and increased the
long-term retrieval of an odor-reward association tested by
a reversal test 1 month after the odor-reward training. The
reference memory was also tested by successive odor-pair
training.Whenkaliotoxinwasinjectedbeforetheacquisition
or retention session it improved performance. Nevertheless,
when kaliotoxin was injected immediately after acquisition
no eﬀect was observed, suggesting that the blockage of Kv1.1
or Kv1.3 channels by kaliotoxin facilitates cognitive processes
as learning, in particular in a reference representation [92].
4.4. Iberiotoxin (IbTx). IbTx, a toxin isolated from venom
of the scorpion Mesobuthus tamulus, is a selective inhibitor
of KCa1.1 channels [121, 122]. These channels have been
identiﬁed in brain regions that are related to cognitionJournal of Toxicology 11
such as the hippocampus [123], and they have also been
implicated in memory processing.
In rabbits, it has been shown a strong relationship be-
tween classical conditioning and membrane excitability in
Purkinje cells which persisted for at least 1 month [124]. In
slicesofcerebellarlobule,theadministrationofIbTXmimics
the increases in membrane excitability related to condition-
ing, suggesting that classical conditioning is dependent upon
the inhibition of KCa1.1 channels [124].
In chicks submitted to passive avoidance task, Edwards
and Rickard [93] showed a transient retention loss (40–
70min after training) associated with the central adminis-
tration of 50nM IbTX immediately after training.
4.5.SpiderKTxs. DespiteKv2channelspossiblycontributing
negatively to the mechanisms of learning and memory and
spider venom being a rich source of gating modiﬁers of Kv2
channels, no evaluation of the use of the spider KTxs as
probes in cognitive processes was carried out so far. Only
one study [125] tested the eﬀect of a spider toxin in mice
submitted to behavioral tests of memory, but this toxin was
not a KTx.
5. Potassium Channels and Clinical Conditions
Holding CognitiveImpairment
The studies presented above suggest that, at least in part,
expression modiﬁcation and conductance modulation of
potassium channels are related to learning and memory pro-
cesses. In some neurological dysfunctions, the relationship
between KCN and cognitive aspects is also evident.
5.1. Limbic Encephalitis. Limbic encephalitis is characterized
by disorientation, agitation, anxiety, depression, irritability,
personality change, acute confusional state, hallucinations,
complex partial and secondary generalized seizures, and,
mainly, by impairment of short-term memory. Limbic
encephalitis may have paraneoplastic or autoimmune origin
(for reviews see [126, 127]).
Some casesoflimbic encephalitis reinforcethatKCNs are
involved in learning and memory processes. Patients with
this clinical condition and high plasma concentration (as
reﬂected in the cerebrospinal ﬂuid) of antibodies against
voltage-dependent potassium channels (anti-Kv)h a ds e v e r e
memory impairment. This cognitive function has a neu-
ropsychological improvement after reducing serum levels of
anti-Kv by plasma exchange, immunosuppressive treatment
or spontaneous fall [126, 128–130].
5.2. Human-Immunodeﬁciency-Virus-Type-1 (HIV-1-) Asso-
ciated Dementia (HAD). HAD is a severe and debili-
tating form of HIV-1-associated neurocognitive disorders
(HANDs). Over 40 million people worldwide are infected
by HIV and 20–30% of them displayed symptoms of HAD.
This disorder is characterized by cognitive deﬁcits, motor
disturbances, and behavioral abnormalities (for reviews see
[131, 132]).
In individuals with HAD, the cognitive deﬁcits could
be result of Kv channels dysfunction [133, 134]. The brain
cortex in individuals with HAD revealed overexpression of
genes coding for KCNs that prolong afterhyperpolarization
[135].
This participation of KCN in memory in the clinical
condition caused by HIV-1 is supported by experimen-
tal results. Injection of HIV-1-infected human monocyte-
derived macrophages into brain of immunodeﬁcient mice, a
model of human HIV-1-encephalitis (HIVE), impaired both
long-term potentiation in hippocampus and spatial learning
[136, 137]. Interestingly, these two damages are reversed
when the HIVE mice received systemic administration of 4-
A P ,aK C Nb l o c k e ra f o r e c i t e d[ 138].
5.3. Schizophrenia. Schizophrenia is a neuropsychiatric dis-
order that aﬀects approximately 0.8% of the world popula-
tion. It is characterized by the presence of several symptoms
that can be grouped into two categories: positive and
negativesymptomsasafunctionofnormalbehavior.Positive
symptoms (in addition to normal behavior) include hal-
lucinations, delusions, and disorganized thoughts. Negative
signs (absent in normal behavior) consist of anhedonia and
social withdrawal [139, 140].
Schizophrenia is associated with cognitive deﬁcits [141].
Weickert et al. [142] found that 51% of 117 patients with
schizophrenia and decline in intelligence quotient (IQ)
also exhibited deﬁcits of executive function, memory, and
attention. Deﬁcits of executive function and memory also
were found in 71% of 73 individuals with schizophrenia that
showed intellectually compromised or deteriorated [143].
This memory deﬁcit observed in patients with
schizophrenia may be also consequence of dysfunction
of potassium channels. Early life exposure of rodents to
maternal separation or social isolation is an animal model
for schizophrenia [144]. Quan et al. [145]o b s e r v e dd e ﬁ c i t s
in learning and memory in postweaning isolation-reared
rats similar to individuals with schizophrenia. When
compared to the housed rats, the isolated ones performed
worse in probe trials and memory retention tests in Morris
water maze. Interestingly, these researchers found that the
amplitudes of hippocampal voltage-dependent transient
potassium A-type (I(A)) currents were enhanced, and the
steady inactivation curve of I(A) currents was shifted towards
positive potential by CSF of isolated rats. These K+ currents
regulate action potential backpropagation and the induction
of speciﬁc forms of synaptic plasticity, which is thought
to underlie learning and memory [146, 147]. Therefore,
Quan et al. [145] suggest that the mechanism by which
early stressful experience leads to long-lasting consequences
for spatial memory involves hippocampal potassium ion
channel currents.
5.4. Alzheimer’s Disease. Disorders that impair mental abil-
ities are among the most feared result of aging. Among
the kind of dementia, Alzheimer’s disease (AD) represents
the substantial majority of cases. AD is a progressive
neurodegenerative disease characterized by loss of function12 Journal of Toxicology
and death of neurons in various areas of the brain, leading
to loss of mental functions such as memory and learning.
The clinical diagnosis of AD is usually done when the
memory loss speeds up, and other behavioral and cognitive
symptoms appear, mainly because the failure in the capacity
torememberordinaryfactsofeverydaylifeiseasilydismissed
as normal aging. The episodic memory is related to the
hippocampus and the interconnections circuits between this
area and cortex goes through changes during aging that
are highly susceptible to neurodegeneration in AD. Unfor-
tunately, by the time of AD diagnosis, prominent neuronal
loss has already occurred in the entorhinal cortex (EC), the
brain’s interface between the hippocampal formation and
neocortex.Itisworthytomentionthatneurodegenerationin
ECdoesnotoccurinhealthybrainsundergoingaging,andas
structural and functional measures of the EC, dentate gyrus
and CA3 region circuit display a progressive change on the
course to AD. This circuit could represent a suitable target to
therapies aimed to modify the disease progression [148].
In addition to the decreased number of acetylcholine
(Ach) receptors in the basal forebrain cholinergic neurons
(BCFN), Kv3.1 and Kv2.1 have been implicated to AD. The
use of immunohistochemical techniques showed that both
KCNs are expressed in the BCFN [149]. BFCN voltage-gated
KCNs regulate Ach release and may participate in BFCN
neurodegeneration in the course of AD.
The accumulation of amyloid beta plaques is an AD
characteristic. It seems that these plaques form calcium-
conducting ion channels that cause rapid neurodegeneration
due to calcium overload [150]. Toxins acting as Ca2+ channel
blockers, such as ω-agatoxin, attenuate the increases in Ca2+
concentration in isolated hippocampal nerve endings in the
rat [149].
I(A) currents and the KCN behind these currents seem
to have a role in AD. KCNs responsible for I(A) currents
have been involved in the onset of long-term potentiation in
mammalian neurons, which is thought to underlie learning
and memory [146, 147]. A change in the steady-state
properties of the I (A) current was showed in the amyloid-
treated Drosophila cholinergic neurons which was suﬃcient
to increase the threshold for the initiation of repetitive ﬁring
[151]. In this study, speciﬁc KTxs of the Kv4.2 channel
(phrixotoxin-2) and Kv1 channel (α-dendrotoxin) were used
to determine which channels triggered these currents in
the Drosophila model. It had been shown that treatment of
cholinergicneuronswithamyloidpeptidealteredthekinetics
of the current and caused a decrease in neuronal viability
[152].
Brain microglia and their KCNs are also important to
AD.Thesecellsareactivatedtoproducea“respiratoryburst,”
which produces reactive oxygen species (ROS) that cause the
death of target cells in pathological states [153]. However,
ROS generated by microglia contribute to the death of
neuronsinneurodegenerativeconditionssuchasAlzheimer’s
and Parkinson’s diseases, HIV and prion infection, and
multiple sclerosis (reviewed by [154]). Kv1.3 and KCa2
and KCa4 are required for the respiratory burst and ROS
formation in cultured microglia, and the inhibition of Kv1.3
by agitoxin-2 prevented neuronal killing by the microglia
[155]. Moreover, charybdotoxin and α-dendrotoxin, all
Kv1.3blockers,reducedneuronkillingbymicrogliaasshown
by transwell cell-culture system [156].
5.5. Multiple Sclerosis. Multiple sclerosis (abbreviated MS,
known as disseminated sclerosis or encephalomyelitis dissem-
inata) is an inﬂammatory disease. In MS, the fatty myelin
sheaths around the axons of the brain and spinal cord
are destroyed, leading to demyelination and scarring as
well as a broad spectrum of signs and symptoms such
as muscular weakness, loss of coordination and speech,
visual disturbances, and cognitive disability. MS is a chronic
degenerative disease and the most common neurological
cause of disability in young adults in industrialized societies
[157]. The major disabling aspect of MS is the cognitive
impairment, which is characterized primarily by memory
loss, attention deﬁcits, slowed information processing, and
failure in executive function [158].
Some MS symptoms may be closely dependent upon
changes in KCN [159]. Kv1.1 and Kv1.2 are speciﬁcally
found in paranodal regions of axons [160]. KCN blockers
such as aminopyridines (APs) when applied in vitro to
demyelinated axons are able to restore the conduction and
also to potentiate synaptic transmission [161–164]. Because
of that, much attention has been given to Kv blockers as a
prospective agent for MS and other neuropathies treatments
[165, 166].
Moreover, MS is a chronic inﬂammatory autoimmune
disease and the central role of T lymphocytes, and their
Kv1.3 and KCa1.1 channels, in its pathogenesis has been
largely evidenced [167–169]. Kaliotoxin, which blocks the
lymphocyte Kv1.3 and the neuronal Kv1.1 channels, amelio-
rates the symptoms of adoptive experimental autoimmune
encephalomyelitis (EAE) in rats [170], a widely used model
for the human MS disease [167]. It is worthy to mention that
4-AP has been used to manage some of the symptoms of MS
[171, 172]. 4-AP was approved by the US Food and Drug
Administration (FDA) on January 22, 2010 for the treatment
of MS [173].
5.6. Parkinson’s Disease. Parkinson’s disease (PD) is a slowly
progressive degenerative disorder of the CNS and is char-
acterized by slowness or deﬁciency of movement (bradyki-
nesia), rigidity, postural instability, and tremor primarily
while at rest. The motor symptoms of PD result from the
death of dopamine-generating cells in the substantia nigra,
a region of the midbrain. In the early stage of the disease,
the most obvious symptoms are those that are movement-
related, such as shaking, rigidity, slowness of movement,
and diﬃculty with walking and gait. With time, cognitive
and behavioral problems may arise, commonly followed by
dementia in the advanced phase of the disease. PD is more
common in the elderly, with most cases occurring after the
age of 50 (for review see [174, 175]).
Potassium channels have been implicated in the patho-
genesis of PD. KATP channels comprised of Kir6.2 and
Sur1 subunit are abundantly expressed in dopaminergic
neurons of substantia nigra [176]. KATP directly couple theJournal of Toxicology 13
cellular metabolic state to membrane excitability. It has
been shown that activity of the mitochondrial respiratory
chain complex I (CXI, also known as NADH: ubiquinone
reductase) is reduced in PD patients, strongly suggesting
that metabolic stress is an important trigger factor for the
PD neurodegeneration. Dopaminergic midbrain neurons
express diﬀerent types of KATP channels mediating their dif-
ferentialresponsetotheinhibitionofmitochondrialcomplex
I[ 177]. The use of CXI inhibitor leads to the activation
of SUR1/Kir6.2-containing KATP channels, which results in
a membrane hyperpolarization of the dopaminergic neuron
thatisassociatedwithacompletelossofspontaneousactivity
[178]. Studies of dopaminergic midbrain neurons in the
weaver mouse, a genetic mouse model of dopaminergic
degenerationsimilartothatinPD[179],sustaintheproposal
of KATP channel activation as a neuroprotective strategy. Up
to now, no KATP channel activators have been described from
arthropod venom.
5.7. Epilepsy. The term epilepsy refers to a group of
neurological disorders, clinically diverse and with multiple
etiologies, characterized by paroxysmal brain discharges
referred to as spontaneous recurrent seizures [180, 181].
Epilepsy is the second most common neurological disorder
(after stroke), aﬀecting 1-2% of the world’s population
[182]. Failure to treat epilepsy causes neurobiological, psy-
chological, and social consequences for the patient [183],
particularly cognitive impairment [184, 185]. Age of onset
of epilepsy, type and duration of seizures, as well as the
antiepileptic drug, therapy are strongly related to cognitive
dysfunction present in the syndrome [186–188].
Clearly,ionchannelsarecriticalforregulatingexcitability
and, contribute signiﬁcantly to epilepsy pathophysiology.
In a recent article, N’Gouemo [189] related that the
loss-of-function large conductance KCa channels mutations
contribute to neuronal hyperexcitability that can lead to
temporal lobe epilepsy, tonic-clonic seizures and alcohol
withdrawal seizures, and blockage of these channels can
trigger seizures and status epilepticus.
Despite its availability, conventional and “new genera-
tion” antiepileptic drugs (AEDs) are commonly associated
with side eﬀects, which can vary in frequency and severity
[190]. In addition, AEDs are ineﬀective in controlling
seizures in one-third of patients (drug-resistant), reaching
70% in patients with temporal lobe epilepsy, which is the
more frequent epilepsy in adults and it is characterized by
degeneration of limbic structures (sclerotic hippocampus),
directly involved in diﬀerent memory processes and in
their modulation [191–194]. It is noteworthy that cognitive
deﬁcits represent a serious neuropsychological problem in
people suﬀering from temporal lobe epilepsy.
Several studies suggest that KCN may be an important
new class of targets for anticonvulsant therapies [195, 196],
especially for refractory epilepsy. New drugs that act on
potassium channels have been provided and approved by
the FDA and the European Union, for example, ezogabine
(retigabine). In vitro studies indicate that ezogabine acts
primarily by opening neuronal Kv7.2–7.5 channels [197].
6.Arthropod Toxins:
Therapeutic andStudy Tools
Given that the dysfunction of K+ channels has signiﬁcant
contribution in cognitive deﬁcits of several neurological
clinical conditions, the drugs that modulate their activity
became important allies in the study and treatment of these
pathologies. Due to the wide presence and diversity of
potassium channels in the brain, these therapeutic agents
need to be speciﬁc and potent. In this way, the toxins from
arthropods turn out to be excellent candidates.
6.1. Potential of KTxs as Pharmacological Tools. KTxs that
act on KCN responsible for I(A) currents are of particular
interest. These channels regulate ﬁring frequency, spike
initiationandwaveforminexcitablecellsandmaycontribute
to specialized functions, such as learning, memory, and
behavior [146, 147]. According to the cell type and to the
molecularheterogeneity,I(A) currentsexhibitawidediversity
of physiological properties. KCNs of subtype Kv4 participate
in the generation of I(A) currents in the cerebellum granular
cells [198], neostriatal cholinergic interneurons [199], and
hippocampal interneurons [147]. Kv2 channels seem to be
equally important for the existence of I(A) currents in neo-
cortical pyramidal neurons [200, 201]. Therefore KTxs that
inﬂuence the I(A)currents, or more speciﬁcally in Kv2 and/or
Kv4 channels activity, become potential pharmacological
tools for studying the participation of KCN in learning
memory and its dysfunctions.
Many scorpion KTxs inﬂuence the I(A)currents. Nox-
iustoxin (NTX), from the venom of the Mexican scorpion
Centruroides noxius Hoﬀmann [202], and discrepin, toxin
fromtheVenezuelanscorpionTityusdiscrepans[203],belong
to α-KTx15 subfamily. Toxins of this subfamily are reported
to aﬀect the I(A) currents [198]. Interesting, discrepin blocks
irreversible K+-channels of rat cerebellum neurons [203].
BmTX3 (systematic name α-KTx 15.2) is toxin isolated
from venom of Manchurian scorpion Mesobuthus martensi
is Karsch. This peptide blocked (Kd = 54nM) completely
the I(A) current of striatum neurons in culture, whereas the
sustained K+ current was unaﬀected. The labeled synthetic
toxin (125I-sBmTX3) was found in the striatum, hippocam-
pus,superiorcolliculus,andcerebellumintheadultratbrain
[204]. BmTx3B (Martentoxin, systematic name alpha-KTx
16.2) is another toxin isolated from Mesobuthus martensi
Karsch. It was tested on two types of voltage-dependent
potassium currents recorded from dissociated hippocampal
neurons of neonatal rat in whole-cell voltage-clamp mode.
BmTx3B selectively inhibited the delayed rectiﬁer potassium
current (I(K)), without aﬀecting the I(A) current [205].
Therefore these scorpions KTxs are candidates to become
tools for the study of KCN in physiological and pathological
mechanisms of learning and memory.
As mentioned above, the spider venom is a source of
KTxs that act on Kv2a n dK v4 channels. The ﬁrst spider
toxins described as KCN blockers were the hanatoxins 1 and
2 (HaTx 1 and 2) of the theraphosidae spider Grammostola
spatulata [206]. Despite the marked diﬀerences in their14 Journal of Toxicology
primary sequence, both blocked the Kv2.1 channel with Kd
of 42nM. HaTxs block Kv1a n dK v3 channels, while the
shal-related channel (type Kv4) is sensitive to the toxin.
The heteropodatoxins (HpTx 1–3), isolated from the venom
of Heteropoda venatoria (Sparassidae), blocked the conduc-
tance of Kv4.2 but not of Kv1.4, in a voltage-dependent
manner. Other toxins that act on KCN were isolated from
the venom of the Theraphosidae Phrixotrichus auratus.T h e
phrixotoxins (Patx 1 and 2) speciﬁcally block Kv4.3 and
Kv4.2 currents at nanomolar concentrations altering the
gating properties of these channels by interacting with the
voltage sensor. The subfamilies of shaker (Kv1), shab (Kv2),
and shaw (Kv3) were not inhibited by PaTxs [207]. The
stromatoxin1, ScTx1, isolated from tarantula Stromatopelma
calceata, was the ﬁrst high-aﬃnity inhibitor described for the
Kv2.2 channel. ScTx1 also inhibited Kv2.1 channels, Kv4.2
and Kv2.1/Kv9.3 heterodimer [208]. HmTx 1 and 2, peptides
puriﬁed from the tarantula spider Heteroscodra maculata,
inhibited potassium currents associated with subtypes Kv2
[206]. Guangitoxin-1E (GxTX-1E) is a potent gating mod-
iﬁer peptide of Kv2 channels isolated from the venom
of the tarantula Plesiophrictus guangxiensis [209]. Other
spider toxins targeting the K+-channel voltage sensor include
heteroscodratoxins (HmTx1,2), which target Kv2a n dK v4
channels [206]; TLTx1–3, which preferentially inhibit Kv4
channels[210];PhTx3-1,whichinhibitstheoutwardrectiﬁer
A-type K+-channel [211]. SGTx1 (Kappa-theraphotoxin-
Scg1a) is a peptide toxin isolated from the venom of the
aggressive African Theraphosidae Scodra griseipes that has
been shown to inhibit outward K+ currents in rat cere-
bellar granule neurons [64]. Functionally, SGTx1 reversibly
inhibits potassium currents in oocytes expressing Kv2.1
channels and acts by shifting the activation of the channel
to more depolarized voltages [212]. Finally, phrixotoxin-
1, a peptide puriﬁed from the venom of the tarantula
Phrixotrichus auratus, is a speciﬁc and potent blocker of
Kv4.3 [207]. So there are many spider KTxs that are potential
tools for the study of KCN in learning and memory and its
dysfunction.
Toxins that act on large-conductance Ca2+-activated
K+-channels (KCa1.1 or BK) and small-conductance Ca2+-
activated K+ channel (KCa2.1 or SK1, KCa2.2 or SK2, and
KCa2.3 or SK3) are important too. Neuronal ﬁring is also
regulated by KCa1.1 and KCa2 which constitute an exclusive
family of ion channels which combine intracellular chemical
changes and electric signaling [213, 214]. KCa1.1 are homol-
ogous to Kv channel α-subunits, but possess additional
hydrophobic segments forming an extracellular N-terminal
and a long intracellular C-terminal that holds one of the
Ca2+-binding sites [215]. It has been reported that KCa
channels are involved in regulation of neocortex pyramidal
cell excitability [216, 217]. Therefore KTxs that inﬂuence the
KCa channels become also potential pharmacological tools.
KCa channels are blocked by many scorpion toxins.
Martentoxin, puriﬁed from Mesobuthus martensi Karsch
venom, is able to block KCa1.1 currents in rat hippocampal
neurons [218]. This KCN is also inhibited by slotoxin from
Centruroidesnoxius[219]andnoxiustoxinfromCentruroides
noxius [220]. Slotoxin is described not only as a potent and
selective blocker, but it also can diﬀerentially inhibit KCa1.1
channels,dependingonthepresenceofβ-subunits[219]and
on the α-splice variant [221]. KCa2 channels are also blocked
by diﬀerent scorpion toxins. For example, there are scylla-
toxin (leiurotoxin I) isolated from Leiurus quinquestriatus
hebraeus[222]andtamapinfromMesobuthus tumulus [223].
This last toxin blocks KCa2 channels in pyramidal neurons of
the hippocampus as well as in cell lines expressing distinct
KCa2 channel subunits, displaying a remarkable selectivity
for KCa2.2 (IC50 = 24pM) versus KCa2.1 (∼ =1750-fold) and
KCa2.3 (∼ =70-fold) channels [223]. These data reinforce the
potential of scorpion KTxs as pharmacological tools.
As has been evident, multiple KCNs participate in the
regulation of cellular events behind the phenomena of
learning and memory and their dysfunctions. Therefore,
it is necessary a varied arsenal of pharmacological tools
to investigate the role of each potassium channel in these
cognitive processes. It also became clear that scorpions and
spiders KTxs can provide this diversity of tools.
7. Conclusion
The KCNs are components of the mechanisms responsible
for learning and memory. Its diversity and wide distribution
in the brain make the action of KCN during the formation of
learning and memory retrieval to be complex and variable.
To investigate the role of each subtype of KCN in these
phenomena, we need also a wide variety of pharmacological
tools, speciﬁc and potent for KCN. The toxins from the
venoms of arthropods can be such tools. These precise
potassium channel toxins may not only have an important
contribution to uncover the processes underlying learning
and memory, but can also become therapeutic agents for
many diseases and disorders of the CNS.
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